Should You Dump AstraZeneca plc In Favour Of GlaxoSmithKline plc?

AstraZeneca plc (LON: AZN) currently trades at a premium to GlaxoSmithKline plc (LON: GSK); does it deserve it?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) have both had very different fortunes since the beginning of the year. On one hand, AstraZeneca’s shares have surged higher around 15%, beating the FTSE 100 approximately 14%. On the other, Glaxo has floundered, rising a lacklustre 5%.

But after this impressive performance, are AstraZeneca’s shares overvalued and should you dump your holding in favour of larger peer Glaxo? 

A quick look at valuation

The quickest way to gauge whether or not AstraZeneca is overvalued is to take a look at the company’s valuation, although this is by no means a definitive analysis.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

At present, Glaxo is currently trading at a forward P/E of 15 for 2014, in comparison, AstraZeneca is trading at a forward P/E of 15.7, which does not seem overly expensive at first glance.

However, AstraZeneca’s earnings per share are expected to fall around 14% during 2014, while Glaxo’s EPS are forecast to remain unchanged, implying that AstraZeneca should actually be trading at a discount to Glaxo. Additionally, Glaxo’s dividend yield now stands at 4.7%, AstraZeneca’s yield currently sits at 4.1%, rising to 4.2% next year. 

The fundamentals support Glaxo

AstraZeneca has been grappling with sliding sales for some time now, thanks to the loss of exclusive manufacturing rights for a number of its treatments. Actually, according to the company’s own management, sales are going to continue to decline for some years to come. Specifically, AstraZeneca’s CEO Pascal Soriot does not expect AstraZeneca’s revenue to return to 2013 levels until 2017. This implies that the market is placing too much of a premium on the company.

Further, AstraZeneca only brought 11 treatments to Phase III trials during 2013 but none of these new products will file for regulatory approval before 2016. In comparison, Glaxo had five new drugs approved for sale during 2013 and a further 40 are in late stage development. With this being the case it would appear silly to suggest that AstraZeneca should trade at the same valuation as Glaxo, which it currently does. 

Summary

All in all, looking at the evidence above, I feel that perhaps investors should dump AstraZeneca in favour of Glaxo.

With multiple new treatments coming to market over the next few years, sales continuing to expand and a dividend yield of 4.7%, Glaxo would appear to be a better choice than AstraZeneca, which continues to report sliding sales and boasts an unimpressive treatment pipeline. 

Of course, there are plenty of other passive income opportunities to explore. And these may be even more lucrative:

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

After collapsing 28% today, are Bunzl shares too cheap to ignore?

A poor trading statement has sent Bunzl shares to multi-year lows. Could now be a good time to consider investing…

Read more »

Investing Articles

These 5 stocks could earn £1,600 of annual passive income in a £20,000 ISA

Harvey Jones shows how to generate a high and rising passive income by buying a balanced mix of high-yielding FTSE…

Read more »

Young woman holding up three fingers
Investing Articles

3 things I like about Greggs shares

Greggs shares have tumbled by more than a third over the past year. But this writer has no plan to…

Read more »

artificial intelligence investing algorithms
Investing Articles

Nvidia stock: beware the bear market rally

Andrew Mackie argues that investors should tread carefully before investing in Nvidia stock, as the worst of the sell-off could…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Up 73% in one year, is this the best value stock in the FTSE 100?

A brilliant run of form suggests this FTSE 100 giant should no longer make the cut as a value stock.…

Read more »

Investing Articles

The best could yet be to come for UK shares! I’m buying these ones

Amid ongoing stock market turbulence, this writer's been adding selected UK shares to his portfolio. Here's why and what he…

Read more »

Top Stocks

4 UK stocks trading well below book value to consider buying

Sometimes, it pays to be contrarian: who says the UK market has priced a stock precisely right, anyway?

Read more »

Investing Articles

The S&P 500’s 12% off its highs. Is now a good time to buy US shares for an ISA?

Right now, a lot of British investors are wondering whether it’s a good time to buy US shares. Here, Edward…

Read more »